JP2009542820A5 - - Google Patents

Download PDF

Info

Publication number
JP2009542820A5
JP2009542820A5 JP2009530701A JP2009530701A JP2009542820A5 JP 2009542820 A5 JP2009542820 A5 JP 2009542820A5 JP 2009530701 A JP2009530701 A JP 2009530701A JP 2009530701 A JP2009530701 A JP 2009530701A JP 2009542820 A5 JP2009542820 A5 JP 2009542820A5
Authority
JP
Japan
Prior art keywords
combination
selective antagonist
antidepressant
selective
telenzepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009530701A
Other languages
English (en)
Japanese (ja)
Other versions
JP5371762B2 (ja
JP2009542820A (ja
Filing date
Publication date
Priority claimed from US11/763,313 external-priority patent/US8748419B2/en
Application filed filed Critical
Publication of JP2009542820A publication Critical patent/JP2009542820A/ja
Publication of JP2009542820A5 publication Critical patent/JP2009542820A5/ja
Application granted granted Critical
Publication of JP5371762B2 publication Critical patent/JP5371762B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009530701A 2006-06-16 2007-06-15 ムスカリン性受容体m1拮抗薬による肥満の処置 Expired - Fee Related JP5371762B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80506606P 2006-06-16 2006-06-16
US60/805,066 2006-06-16
US82922506P 2006-10-12 2006-10-12
US60/829,225 2006-10-12
US11/763,313 2007-06-14
US11/763,313 US8748419B2 (en) 2006-06-16 2007-06-14 Treating obesity with muscarinic receptor M1 antagonists
PCT/US2007/071374 WO2007147134A2 (en) 2006-06-16 2007-06-15 Treating obesity with muscarinic receptor m1 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013001003A Division JP2013079277A (ja) 2006-06-16 2013-01-08 ムスカリン性受容体m1拮抗薬による肥満の処置

Publications (3)

Publication Number Publication Date
JP2009542820A JP2009542820A (ja) 2009-12-03
JP2009542820A5 true JP2009542820A5 (cg-RX-API-DMAC7.html) 2011-07-14
JP5371762B2 JP5371762B2 (ja) 2013-12-18

Family

ID=38832915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009530701A Expired - Fee Related JP5371762B2 (ja) 2006-06-16 2007-06-15 ムスカリン性受容体m1拮抗薬による肥満の処置
JP2013001003A Withdrawn JP2013079277A (ja) 2006-06-16 2013-01-08 ムスカリン性受容体m1拮抗薬による肥満の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013001003A Withdrawn JP2013079277A (ja) 2006-06-16 2013-01-08 ムスカリン性受容体m1拮抗薬による肥満の処置

Country Status (13)

Country Link
US (1) US8748419B2 (cg-RX-API-DMAC7.html)
EP (1) EP2031964B1 (cg-RX-API-DMAC7.html)
JP (2) JP5371762B2 (cg-RX-API-DMAC7.html)
KR (1) KR101442525B1 (cg-RX-API-DMAC7.html)
AU (1) AU2007260642B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0713728A2 (cg-RX-API-DMAC7.html)
CA (1) CA2655323C (cg-RX-API-DMAC7.html)
IL (1) IL195858A (cg-RX-API-DMAC7.html)
MX (1) MX2008015886A (cg-RX-API-DMAC7.html)
NZ (1) NZ573571A (cg-RX-API-DMAC7.html)
SG (1) SG172711A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007147134A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200810681B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021507A1 (en) * 2009-07-22 2011-01-27 Theracos, Inc. Inhibiting antipsychotic-induced weight gain
WO2011163231A2 (en) * 2010-06-21 2011-12-29 Theracos, Inc. Combination therapy for the treatment of diabetes
EP3363439B1 (en) * 2010-10-25 2025-01-08 University Of Manitoba Therapeutic compositions for diabetic symmetrical polyneuropathy
WO2013151596A2 (en) * 2012-04-05 2013-10-10 Finch Linda Duerler System and method of losing weight
CN109475635A (zh) * 2016-03-15 2019-03-15 玛丽女王伦敦大学 治疗肥胖症的方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795183B1 (de) 1968-08-20 1972-07-20 Thomae Gmbh Dr K 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate und Arzneimittel
US4172831A (en) 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
US3953430A (en) 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
US4168269A (en) 1978-04-12 1979-09-18 American Cyanamid Company Substituted thieno-benzodiazepines
US4381301A (en) 1980-05-07 1983-04-26 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted tricyclic thieno compounds, their synthesis, their use, their compositions and their medicaments
US4933438A (en) 1984-02-29 1990-06-12 University Of Florida Brain-specific analogues of centrally acting amines
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3855159D1 (de) 1987-12-22 1996-05-02 Byk Gulden Lomberg Chem Fab Thienotricyclen zur Behandlung von Erkrankungen der Bronchien
US5668155A (en) 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5344832A (en) 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5585347A (en) 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
DE69229781T2 (de) 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5324832A (en) 1991-07-03 1994-06-28 The United States Of America As Represented By The Department Of Health And Human Services Muscarinic antagonists
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
FR2710265B1 (fr) 1993-09-22 1995-10-20 Adir Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
DE19541260A1 (de) 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
PT863136E (pt) 1997-02-25 2004-01-30 Akzo Nobel Nv Derivados de azetidina e de pirrolidina
US5795895A (en) * 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
AU9062998A (en) 1997-09-11 1999-03-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6248864B1 (en) 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
EP1052994A2 (en) 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
IL141762A0 (en) 1998-10-01 2002-03-10 Novartis Ag New oral formulations
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2792527B1 (fr) 1999-04-22 2004-08-13 Ethypharm Lab Prod Ethiques Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
BR0013720A (pt) 1999-09-02 2002-07-23 Nostrum Pharmaceuticals Inc Formulação em pelota de liberação controlada
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6080736A (en) 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6482439B2 (en) 1999-12-29 2002-11-19 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
WO2002022579A2 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
AU2003231788B2 (en) 2002-05-17 2008-09-11 Duke University Method for treating obesity
WO2004078113A2 (en) * 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050226920A1 (en) 2004-04-13 2005-10-13 Kirk Voelker Method of decreasing nicotine withdrawal symptoms during smoking cessation.
CA2553309A1 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
CA2576153A1 (en) 2004-08-05 2006-02-16 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20090156581A1 (en) * 2005-04-15 2009-06-18 Board Of Trustrees Of Michigan State University Aminergic pharmaceutical compositions and methods
US8859585B2 (en) 2005-05-25 2014-10-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Scopolamine for the treatment of depression and anxiety
CN101401132B (zh) 2006-03-14 2011-05-25 Nxp股份有限公司 自动配置的智能卡及自动配置智能卡的方法
CN101472476B (zh) 2006-06-16 2013-10-30 泰拉科斯有限公司 毒蕈碱型受体m1拮抗剂在制备治疗肥胖症的药物中的应用
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists

Similar Documents

Publication Publication Date Title
RU2019143572A (ru) Композиции для лечения посттравматического стрессового расстройства
JP2009542819A5 (cg-RX-API-DMAC7.html)
JP2012036212A5 (cg-RX-API-DMAC7.html)
JP2013544850A5 (cg-RX-API-DMAC7.html)
JP2023100904A5 (cg-RX-API-DMAC7.html)
JP2008528510A5 (cg-RX-API-DMAC7.html)
RU2012152922A (ru) Лечение психологических состояний с применением антагонистов м1-мускариновых рецепторов
JP2016506933A5 (cg-RX-API-DMAC7.html)
RU2007103313A (ru) Комбинация бупропина и другого состава для эффективной потери веса
JP2010534676A5 (cg-RX-API-DMAC7.html)
JP2005523334A5 (cg-RX-API-DMAC7.html)
RU2008150624A (ru) Лечение депрессивных расстройств
JP2007533686A5 (cg-RX-API-DMAC7.html)
JP2009538331A5 (cg-RX-API-DMAC7.html)
JP2013543482A5 (cg-RX-API-DMAC7.html)
Rogóz et al. Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats
JP2020533415A5 (cg-RX-API-DMAC7.html)
KR20060032598A (ko) 세로토닌 재흡수 억제제 및 아고멜라틴의 조합
WO2012111011A3 (en) Low dosage combinations of fluoxetine and reboxetine for treating obesity
JP2007513052A5 (cg-RX-API-DMAC7.html)
JP2007505156A5 (cg-RX-API-DMAC7.html)
RU2009101146A (ru) Лечение ожирения антагонистами мускаринового рецептора м1
WO2004100939B1 (en) Combination of the analeptic modafinil and an antidepressant for the treatment of depression
NO334448B1 (no) Farmasøytisk preparat som omfatter modafinil og et antidepressivt middel
JP2007513896A5 (cg-RX-API-DMAC7.html)